Paulander Wilhelm, Maisnier-Patin Sophie, Andersson Dan I
Department of Bacteriology, Swedish Institute for Infectious Disease Control and Microbiology, Tumor and Cell Biology Center, Karolinska Institute, S-171 82 Solna, Sweden.
Mol Microbiol. 2007 May;64(4):1038-48. doi: 10.1111/j.1365-2958.2007.05713.x.
We examined how the fitness costs of mupirocin resistance caused by mutations in the chromosomal isoleucyl-tRNA synthetase gene (ileS) can be ameliorated. Mupirocin-resistant mutants were isolated and four different, resistance-conferring point mutations in the chromosomal ileS gene were identified. Fifty independent lineages of the low-fitness, resistant mutants were serially passaged to evolve compensated mutants with increased fitness. In 34/50 of the evolved lineages, the increase in fitness resulted from additional point mutations in isoleucine tRNA synthetase (IleRS). Measurements in vitro of the kinetics of aminoacylation of wild-type and mutant enzymes showed that resistant IleRS had a reduced rate of aminoacylation due to altered interactions with both tRNAIle and ATP. The intragenic compensatory mutations improved IleRS kinetics towards the wild-type enzyme, thereby restoring bacterial fitness. Seven of the 16 lineages that lacked second-site compensatory mutations in ileS, showed an increase in ileS gene dosage, suggesting that an increased level of defective IleRS compensate for the decrease in aminoacylation activity. Our findings show that the fitness costs of ileS mutations conferring mupirocin resistance can be reduced by several types of mechanisms that may contribute to the stability of mupirocin resistance in clinical settings.
我们研究了如何改善由染色体异亮氨酰 - tRNA合成酶基因(ileS)突变引起的莫匹罗星耐药性的适应性代价。分离出莫匹罗星耐药突变体,并鉴定了染色体ileS基因中的四种不同的耐药性赋予点突变。对低适应性的耐药突变体的五十个独立谱系进行连续传代,以进化出适应性增加的补偿突变体。在34/50的进化谱系中,适应性的增加是由于异亮氨酸tRNA合成酶(IleRS)中的额外点突变所致。对野生型和突变型酶的氨酰化动力学进行的体外测量表明,耐药性IleRS由于与tRNAIle和ATP的相互作用改变而导致氨酰化速率降低。基因内补偿突变改善了IleRS对野生型酶的动力学,从而恢复了细菌的适应性。在ileS中缺乏第二位点补偿突变的16个谱系中的7个,显示ileS基因剂量增加,表明缺陷IleRS水平的增加补偿了氨酰化活性的降低。我们的研究结果表明,赋予莫匹罗星耐药性的ileS突变的适应性代价可以通过几种机制降低,这些机制可能有助于临床环境中莫匹罗星耐药性的稳定性。